Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SONIBEC trial of tailored sonidegib scheduling after complete response in locally advanced basal cell carcinoma
2020-002613-17Phase 2Active
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Oct 2020
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonidegib in basal cell carcinoma (BCC), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Maintenance of tailored sonidegib treatment at 12 months. Started Oct 2020; status: active.
02
Drugs
sonidegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2020-002613-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002613-17.